Gamma-hydroxybutyrate Composition for Fed-State Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for narcolepsy, such as sodium oxybate (Xyrem®), require patients to take the first dose at least 2 hours after eating due to significant food-induced reduction in bioavailability, leading to reduced patient compliance, efficacy, and safety, as well as increased risk of abuse.
Innovation Solution
Development of an oral pharmaceutical composition of gamma-hydroxybutyrate (GHB) that can be administered less than two hours after eating, featuring a modified release formulation that maintains bioequivalence to immediate release liquid solutions of sodium oxybate administered at least two hours after eating, thereby overcoming the food effect on absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate release liquid solution of sodium oxybate is administered, then rapid sleep onset is achieved, but food significantly reduces bioavailability requiring dosing at least 2 hours after eating
Solution Approach 1:
The patent divides the dosage into two distinct components: an immediate-release portion (4.5-7.5 grams) that provides rapid sleep onset, and an extended-release portion (3-4.5 grams) that maintains therapeutic levels throughout the night. This segmentation allows each component to fulfill its specific function while overcoming the food effect limitation of immediate-release formulations alone
Solution Approach 2:
The patent modifies the release rate parameter of gamma-hydroxybutyrate by using different formulation technologies for the two portions. The immediate-release portion uses standard liquid or capsule formulation for rapid absorption, while the extended-release portion uses controlled-release technology to maintain steady plasma concentrations over 6-8 hours, thereby achieving reliable efficacy regardless of food intake timing
2Reliability
If dosing is required at least 2 hours after eating, then bioavailability is maintained, but patient compliance and convenience are reduced
Solution Approach 1:
The patent creates a dynamic dosing system where the extended-release portion adapts to the patient's sleep duration by maintaining therapeutic plasma concentrations throughout the night. This dynamic release profile eliminates the need for strict pre-dosing timing relative to meals, as the formulation ensures adequate drug levels regardless of when the dose is taken in relation to food intake
Solution Approach 2:
The extended-release portion acts as an intermediary that bridges the gap between the immediate-release dose and the patient's wake time. This intermediate sustained-release component ensures that therapeutic levels are maintained throughout the night, eliminating the need for patients to precisely time their dose relative to meals while still achieving reliable bioavailability
3Reliability
If higher doses are administered to overcome food effect, then adequate plasma levels may be achieved, but adverse events and abuse risk increase
Solution Approach 1:
The patent uses periodic action by administering the dose in two distinct phases: an immediate-release phase that quickly achieves therapeutic levels for sleep onset, and an extended-release phase that maintains levels throughout the night. This periodic delivery pattern prevents the need for high single doses, thereby reducing adverse events while ensuring adequate plasma concentrations are maintained throughout the treatment period
Solution Approach 2:
The patent applies partial action by dividing the total therapeutic dose into two portions with different release characteristics. The immediate-release portion provides sufficient initial concentration for sleep onset without requiring excessive dosing, while the extended-release portion maintains adequate levels throughout the night. This partial dosing strategy in two phases avoids the adverse events associated with high single doses while ensuring therapeutic efficacy
Data Source
AI summary
Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.